» Articles » PMID: 21156726

Epigenetic Suppression of the TGF-beta Pathway Revealed by Transcriptome Profiling in Ovarian Cancer

Overview
Journal Genome Res
Specialty Genetics
Date 2010 Dec 16
PMID 21156726
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies. Diagnosis usually occurs after metastatic spread, largely reflecting vague symptoms of early disease combined with lack of an effective screening strategy. Epigenetic mechanisms of gene regulation, including DNA methylation, are fundamental to normal cellular function and also play a major role in carcinogenesis. To elucidate the biological and clinical relevance of DNA methylation in ovarian cancer, we conducted expression microarray analysis of 39 cell lines and 17 primary culture specimens grown in the presence or absence of DNA methyltransferase (DNMT) inhibitors. Two parameters, induction of expression and standard deviation among untreated samples, identified 378 candidate methylated genes, many relevant to TGF-beta signaling. We analyzed 43 of these genes and they all exhibited methylation. Treatment with DNMT inhibitors increased TGF-beta pathway activity. Hierarchical clustering of ovarian cancers using the 378 genes reproducibly generated a distinct gene cluster strongly correlated with TGF-beta pathway activity that discriminates patients based on age. These data suggest that accumulation of age-related epigenetic modifications leads to suppression of TGF-beta signaling and contributes to ovarian carcinogenesis.

Citing Articles

Genomic analyses of intricate interaction of TE-lncRNA overlapping genes with miRNAs in human diseases.

Lee D, Park E, Kim J, Shin H, Lee Y, Jeong H Genes Genomics. 2024; 46(11):1313-1325.

PMID: 39215947 DOI: 10.1007/s13258-024-01547-1.


Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer.

Bai Y, Li L, Li J, Lu X Heliyon. 2024; 10(9):e30727.

PMID: 38774095 PMC: 11107115. DOI: 10.1016/j.heliyon.2024.e30727.


Current data and future perspectives on DNA methylation in ovarian cancer (Review).

Fu M, Deng F, Chen J, Fu L, Lei J, Xu T Int J Oncol. 2024; 64(6).

PMID: 38757340 PMC: 11095605. DOI: 10.3892/ijo.2024.5650.


Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.

Chien W, Tyner J, Gery S, Zheng Y, Li L, Gopinatha Pillai M J Ovarian Res. 2023; 16(1):80.

PMID: 37087441 PMC: 10122390. DOI: 10.1186/s13048-023-01160-y.


Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance.

Visco Z, Sfakianos G, Grenier C, Boudreau M, Simpson S, Rodriguez I Front Oncol. 2021; 11:620873.

PMID: 33828978 PMC: 8019902. DOI: 10.3389/fonc.2021.620873.


References
1.
Wen X, Akiyama Y, Baylin S, Yuasa Y . Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene. 2005; 25(18):2666-73. DOI: 10.1038/sj.onc.1209297. View

2.
Herfs M, Hubert P, Kholod N, Caberg J, Gilles C, Berx G . Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol. 2008; 172(5):1391-402. PMC: 2329847. DOI: 10.2353/ajpath.2008.071004. View

3.
Chang J, Nevins J . GATHER: a systems approach to interpreting genomic signatures. Bioinformatics. 2006; 22(23):2926-33. DOI: 10.1093/bioinformatics/btl483. View

4.
Dunfield L, Dwyer E, Nachtigal M . TGF beta-induced Smad signaling remains intact in primary human ovarian cancer cells. Endocrinology. 2002; 143(4):1174-81. DOI: 10.1210/endo.143.4.8733. View

5.
Lounis H, Provencher D, Godbout C, Fink D, Milot M, Mes-Masson A . Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res. 1994; 215(2):303-9. DOI: 10.1006/excr.1994.1346. View